
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Georgia Sloboda is managing director of Chemistry Manufacturing and Controls, Sia/LBG.
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.